These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 1700245)

  • 1. Fludarabine for prolymphocytic leukaemia and risk of interstitial pneumonitis.
    Cervantes F; Salgado C; Montserrat E; Rozman C
    Lancet; 1990 Nov; 336(8723):1130. PubMed ID: 1700245
    [No Abstract]   [Full Text] [Related]  

  • 2. Pulmonary toxicity associated with fludarabine monophosphate.
    Hurst PG; Habib MP; Garewal H; Bluestein M; Paquin M; Greenberg BR
    Invest New Drugs; 1987; 5(2):207-10. PubMed ID: 2443463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fludarabine monophosphate for prolymphocytic leukaemia.
    Smith OP; Mehta AB
    Lancet; 1990 Sep; 336(8718):820. PubMed ID: 1698237
    [No Abstract]   [Full Text] [Related]  

  • 4. Tumor lysis syndrome complicating treatment of chronic lymphocytic leukemia with fludarabine phosphate.
    List AF; Kummet TD; Adams JD; Chun HG
    Am J Med; 1990 Sep; 89(3):388-90. PubMed ID: 1697447
    [No Abstract]   [Full Text] [Related]  

  • 5. Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia.
    Schilling PJ; Vadhan-Raj S
    N Engl J Med; 1990 Sep; 323(12):833-4. PubMed ID: 1697401
    [No Abstract]   [Full Text] [Related]  

  • 6. Pulmonary toxicity and acute respiratory failure associated with fludarabine monophosphate.
    Kane GC; McMichael AJ; Patrick H; Erslev AJ
    Respir Med; 1992 May; 86(3):261-3. PubMed ID: 1377831
    [No Abstract]   [Full Text] [Related]  

  • 7. Tumor lysis syndrome induced by fludarabine monophosphate: a case report.
    Nakhoul F; Green J; Abassi ZA; Carter A
    Eur J Haematol; 1996 Apr; 56(4):254-5. PubMed ID: 8641396
    [No Abstract]   [Full Text] [Related]  

  • 8. Fludarabine in chronic leukaemia.
    Astrow AB
    Lancet; 1996 May; 347(9013):1420-1. PubMed ID: 8676619
    [No Abstract]   [Full Text] [Related]  

  • 9. Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia.
    Grever MR; Kopecky KJ; Coltman CA; Files JC; Greenberg BR; Hutton JJ; Talley R; Von Hoff DD; Balcerzak SP
    Nouv Rev Fr Hematol (1978); 1988; 30(5-6):457-9. PubMed ID: 2464793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Phase II clinical study of SH L 573 (fludarabine phosphate) in patients with chronic lymphocytic leukemia].
    Miyawaki S; Imamura M; Kobayashi S; Ohnishi K; Hodohara K; Mizoguchi H; Tomonaga M; Tango T; Ohno R
    Rinsho Ketsueki; 1999 Dec; 40(12):1236-44. PubMed ID: 10658476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fludarabine phosphate in the treatment of chronic lymphocytic leukemia: biology, clinical impact, and future directions.
    Robertson LE; Keating MJ
    Cancer Treat Res; 1993; 64():105-19. PubMed ID: 7680874
    [No Abstract]   [Full Text] [Related]  

  • 12. Fludarabine shows promise for some leukemia patients.
    Oncology (Williston Park); 1989 Mar; 3(3):14. PubMed ID: 2484283
    [No Abstract]   [Full Text] [Related]  

  • 13. [Phase I clinical study of SH L573 (fludarabine phosphate) in patients with chronic lymphocytic leukemia and adult T-cell leukemia/lymphoma].
    Arima N; Mizoguchi H; Shirakawa S; Tomonaga M; Takatsuki K; Ohno R
    Gan To Kagaku Ryoho; 1999 Apr; 26(5):619-29. PubMed ID: 10234292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of advanced chronic lymphocytic leukemia by fludarabine. Results of a clinical phase-II study.
    Hiddemann W; Rottmann R; Wörmann B; Thiel A; Essink M; Ottensmeier C; Freund M; Büchner T; van de Loo J
    Ann Hematol; 1991 Jul; 63(1):1-4. PubMed ID: 1715191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia.
    Keating MJ; Kantarjian H; O'Brien S; Koller C; Talpaz M; Schachner J; Childs CC; Freireich EJ; McCredie KB
    J Clin Oncol; 1991 Jan; 9(1):44-9. PubMed ID: 1702145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fludarabine phosphate--looking forward.
    Cheson BD
    Semin Oncol; 1990 Oct; 17(5 Suppl 8):1-2. PubMed ID: 1699277
    [No Abstract]   [Full Text] [Related]  

  • 17. [Fludarabine monophosphate in the treatment of patients with advanced stages of chronic B-cell lymphatic leukemia resistant to conventional chemotherapy].
    Papajík T; Faber E; Hubácek J; Slezák P; Raida L; Heczko M; Sulovská I; Jarosová M; Pikalová Z; Indrák K
    Vnitr Lek; 1997 Jan; 43(1):25-8. PubMed ID: 9221561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infectious complications of purine analog therapy.
    Samonis G; Kontoyiannis DP
    Curr Opin Infect Dis; 2001 Aug; 14(4):409-13. PubMed ID: 11964857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fludarabine phosphate: an effective therapy for lymphoid malignancies.
    Semin Oncol; 1990 Oct; 17(5 Suppl 8):1-78. PubMed ID: 1699278
    [No Abstract]   [Full Text] [Related]  

  • 20. Fludarabine monophosphate in refractory B-chronic lymphocytic leukemia: maintenance may be significant to sustain response.
    Angelopoulou MA; Poziopoulos C; Boussiotis VA; Kontopidou F; Pangalis GA
    Leuk Lymphoma; 1996 Apr; 21(3-4):321-4. PubMed ID: 8726414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.